 Suchitra Rao
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 23 | 2024 | 543 | 8.490 |
Why?
| | Influenza Vaccines | 13 | 2024 | 497 | 3.760 |
Why?
| | Respiratory Tract Infections | 5 | 2023 | 319 | 2.480 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2023 | 60 | 2.380 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2023 | 97 | 2.310 |
Why?
| | Vaccination | 15 | 2024 | 1202 | 2.270 |
Why?
| | Hospitalization | 23 | 2024 | 1762 | 1.610 |
Why?
| | Influenza A Virus, H1N1 Subtype | 4 | 2023 | 138 | 1.590 |
Why?
| | Child | 39 | 2024 | 18401 | 1.180 |
Why?
| | Coinfection | 2 | 2022 | 120 | 1.080 |
Why?
| | Connective Tissue Diseases | 2 | 2023 | 71 | 1.040 |
Why?
| | Child, Preschool | 24 | 2023 | 9114 | 1.040 |
Why?
| | Infant | 19 | 2023 | 7943 | 1.030 |
Why?
| | Polyomavirus Infections | 3 | 2016 | 22 | 0.980 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2024 | 40 | 0.970 |
Why?
| | Polyomavirus | 3 | 2016 | 8 | 0.940 |
Why?
| | Immunocompromised Host | 3 | 2021 | 192 | 0.920 |
Why?
| | Colorado | 12 | 2023 | 4090 | 0.910 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2023 | 68 | 0.900 |
Why?
| | Retrospective Studies | 20 | 2024 | 12521 | 0.900 |
Why?
| | Ageusia | 1 | 2022 | 1 | 0.840 |
Why?
| | Metapneumovirus | 1 | 2022 | 12 | 0.810 |
Why?
| | Humans | 74 | 2024 | 114045 | 0.800 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2021 | 148 | 0.800 |
Why?
| | Antiviral Agents | 4 | 2024 | 642 | 0.750 |
Why?
| | Myocarditis | 1 | 2022 | 93 | 0.750 |
Why?
| | Viruses | 1 | 2022 | 94 | 0.740 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 92 | 0.700 |
Why?
| | Endpoint Determination | 1 | 2020 | 68 | 0.690 |
Why?
| | Seizures | 2 | 2020 | 337 | 0.670 |
Why?
| | Respiratory Tract Diseases | 2 | 2021 | 139 | 0.650 |
Why?
| | Advisory Committees | 1 | 2020 | 207 | 0.650 |
Why?
| | Streptococcal Infections | 1 | 2021 | 127 | 0.650 |
Why?
| | Birth Order | 1 | 2019 | 12 | 0.640 |
Why?
| | Sinusitis | 1 | 2021 | 174 | 0.630 |
Why?
| | Onchocerciasis | 2 | 2015 | 7 | 0.620 |
Why?
| | Encephalitis | 2 | 2017 | 126 | 0.610 |
Why?
| | Viral Load | 4 | 2024 | 405 | 0.570 |
Why?
| | Nervous System Diseases | 1 | 2020 | 254 | 0.550 |
Why?
| | Emergency Service, Hospital | 14 | 2024 | 1815 | 0.550 |
Why?
| | Adolescent | 27 | 2024 | 17800 | 0.550 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 295 | 0.530 |
Why?
| | Medical Audit | 1 | 2016 | 75 | 0.520 |
Why?
| | Oseltamivir | 1 | 2016 | 11 | 0.510 |
Why?
| | Male | 30 | 2024 | 55396 | 0.500 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 72 | 0.490 |
Why?
| | Spinal Cord Diseases | 1 | 2015 | 38 | 0.480 |
Why?
| | Case-Control Studies | 9 | 2023 | 3003 | 0.480 |
Why?
| | Seasons | 5 | 2024 | 440 | 0.470 |
Why?
| | Acyclovir | 1 | 2015 | 100 | 0.460 |
Why?
| | Female | 30 | 2024 | 59324 | 0.460 |
Why?
| | Attitude to Health | 1 | 2017 | 398 | 0.460 |
Why?
| | Enterovirus Infections | 1 | 2016 | 160 | 0.450 |
Why?
| | Ambulatory Care | 6 | 2023 | 479 | 0.450 |
Why?
| | Health Promotion | 1 | 2019 | 675 | 0.440 |
Why?
| | Mothers | 1 | 2019 | 650 | 0.430 |
Why?
| | Cohort Studies | 8 | 2023 | 4883 | 0.420 |
Why?
| | Infection Control | 1 | 2014 | 132 | 0.420 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1518 | 0.410 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 478 | 0.400 |
Why?
| | Cross Infection | 1 | 2014 | 194 | 0.400 |
Why?
| | Health Personnel | 1 | 2017 | 569 | 0.400 |
Why?
| | Virus Diseases | 1 | 2014 | 195 | 0.390 |
Why?
| | Hematologic Diseases | 1 | 2011 | 55 | 0.360 |
Why?
| | Infant, Newborn | 7 | 2023 | 5038 | 0.360 |
Why?
| | Outpatients | 2 | 2024 | 325 | 0.350 |
Why?
| | Parents | 1 | 2017 | 1181 | 0.340 |
Why?
| | Stomach Rupture | 1 | 2009 | 2 | 0.320 |
Why?
| | Liver Abscess, Amebic | 1 | 2009 | 3 | 0.320 |
Why?
| | Pericardial Effusion | 1 | 2009 | 21 | 0.320 |
Why?
| | Pleural Effusion | 1 | 2009 | 46 | 0.310 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 637 | 0.310 |
Why?
| | Adult | 24 | 2024 | 30375 | 0.300 |
Why?
| | Peritonitis | 1 | 2009 | 77 | 0.300 |
Why?
| | Pandemics | 3 | 2023 | 1310 | 0.300 |
Why?
| | Immunization, Secondary | 3 | 2022 | 82 | 0.290 |
Why?
| | Motivation | 2 | 2022 | 488 | 0.280 |
Why?
| | Angiostrongylus cantonensis | 2 | 2018 | 3 | 0.260 |
Why?
| | Strongylida Infections | 2 | 2018 | 6 | 0.260 |
Why?
| | Young Adult | 9 | 2022 | 10444 | 0.260 |
Why?
| | Electronic Health Records | 3 | 2023 | 799 | 0.250 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 124 | 0.240 |
Why?
| | United States | 15 | 2024 | 12137 | 0.230 |
Why?
| | Physicians | 2 | 2023 | 765 | 0.220 |
Why?
| | Ritonavir | 1 | 2024 | 71 | 0.220 |
Why?
| | Severity of Illness Index | 3 | 2022 | 2537 | 0.210 |
Why?
| | Risk Factors | 5 | 2024 | 8614 | 0.210 |
Why?
| | Vaccines, Combined | 4 | 2023 | 46 | 0.210 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2016 | 314 | 0.210 |
Why?
| | Inpatients | 2 | 2017 | 378 | 0.210 |
Why?
| | Propensity Score | 1 | 2024 | 225 | 0.210 |
Why?
| | Child, Hospitalized | 1 | 2023 | 38 | 0.210 |
Why?
| | Vital Signs | 1 | 2022 | 37 | 0.200 |
Why?
| | Prospective Studies | 3 | 2024 | 6195 | 0.200 |
Why?
| | Viral Vaccines | 1 | 2023 | 88 | 0.200 |
Why?
| | Cough | 1 | 2022 | 107 | 0.200 |
Why?
| | Anticonvulsants | 1 | 2023 | 178 | 0.190 |
Why?
| | RNA, Messenger | 6 | 2023 | 2550 | 0.190 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.190 |
Why?
| | Absenteeism | 1 | 2020 | 40 | 0.170 |
Why?
| | Confusion | 1 | 2020 | 25 | 0.170 |
Why?
| | Antibodies, Viral | 2 | 2023 | 520 | 0.170 |
Why?
| | Critical Pathways | 1 | 2020 | 76 | 0.170 |
Why?
| | Encephalitis, Viral | 1 | 2020 | 39 | 0.170 |
Why?
| | Immunization Schedule | 2 | 2021 | 183 | 0.160 |
Why?
| | Brain Diseases | 1 | 2020 | 124 | 0.160 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 285 | 0.160 |
Why?
| | Education, Medical, Continuing | 1 | 2019 | 115 | 0.160 |
Why?
| | Oxygen | 1 | 2023 | 851 | 0.150 |
Why?
| | Needs Assessment | 1 | 2020 | 315 | 0.150 |
Why?
| | Information Dissemination | 1 | 2020 | 185 | 0.150 |
Why?
| | Interprofessional Relations | 1 | 2020 | 246 | 0.150 |
Why?
| | Infant, Small for Gestational Age | 1 | 2019 | 75 | 0.150 |
Why?
| | Infant, Low Birth Weight | 1 | 2019 | 124 | 0.150 |
Why?
| | Communicable Diseases | 1 | 2020 | 127 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2020 | 219 | 0.150 |
Why?
| | Reminder Systems | 1 | 2019 | 159 | 0.150 |
Why?
| | Disease Outbreaks | 2 | 2020 | 305 | 0.150 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 206 | 0.150 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 60 | 0.150 |
Why?
| | Neoplasms | 1 | 2011 | 2086 | 0.150 |
Why?
| | Body Mass Index | 2 | 2022 | 1957 | 0.150 |
Why?
| | Cost of Illness | 2 | 2016 | 254 | 0.150 |
Why?
| | Nurses | 1 | 2019 | 145 | 0.140 |
Why?
| | Adiposity | 1 | 2022 | 458 | 0.140 |
Why?
| | Critical Care | 1 | 2021 | 472 | 0.140 |
Why?
| | Fatigue | 1 | 2018 | 294 | 0.140 |
Why?
| | Tertiary Healthcare | 1 | 2016 | 28 | 0.130 |
Why?
| | Philippines | 1 | 2016 | 50 | 0.130 |
Why?
| | Urban Population | 1 | 2019 | 396 | 0.130 |
Why?
| | Epidemiologic Studies | 1 | 2016 | 57 | 0.130 |
Why?
| | Program Evaluation | 1 | 2020 | 820 | 0.130 |
Why?
| | Nasal Cavity | 1 | 2016 | 46 | 0.130 |
Why?
| | Onchocerca | 1 | 2015 | 2 | 0.130 |
Why?
| | Middle Aged | 12 | 2024 | 26605 | 0.130 |
Why?
| | Aged | 9 | 2024 | 18969 | 0.130 |
Why?
| | Zoonoses | 1 | 2015 | 21 | 0.130 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 28 | 0.130 |
Why?
| | Rural Population | 1 | 2019 | 443 | 0.120 |
Why?
| | Dog Diseases | 1 | 2015 | 41 | 0.120 |
Why?
| | Computational Biology | 1 | 2019 | 528 | 0.120 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2015 | 19 | 0.120 |
Why?
| | Electroencephalography | 1 | 2017 | 359 | 0.120 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 20 | 0.120 |
Why?
| | Drug Utilization | 1 | 2016 | 164 | 0.120 |
Why?
| | Incidence | 1 | 2021 | 2314 | 0.120 |
Why?
| | Hospitals | 3 | 2024 | 581 | 0.120 |
Why?
| | Pregnancy | 3 | 2022 | 5499 | 0.110 |
Why?
| | Cervical Vertebrae | 1 | 2015 | 104 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2022 | 6306 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2015 | 370 | 0.110 |
Why?
| | Transcriptome | 1 | 2019 | 723 | 0.110 |
Why?
| | Patient Discharge | 1 | 2019 | 770 | 0.110 |
Why?
| | Quality Improvement | 1 | 2020 | 944 | 0.110 |
Why?
| | Survival Rate | 1 | 2017 | 1638 | 0.100 |
Why?
| | Decision Making | 1 | 2018 | 760 | 0.100 |
Why?
| | Meningitis | 1 | 2013 | 74 | 0.100 |
Why?
| | Logistic Models | 1 | 2016 | 1829 | 0.100 |
Why?
| | Critical Illness | 1 | 2016 | 640 | 0.090 |
Why?
| | Registries | 1 | 2019 | 1764 | 0.090 |
Why?
| | Time Factors | 3 | 2022 | 6077 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1204 | 0.090 |
Why?
| | Eosinophilia | 1 | 2013 | 186 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 95 | 0.090 |
Why?
| | Internship and Residency | 1 | 2019 | 920 | 0.090 |
Why?
| | Pediatrics | 1 | 2017 | 982 | 0.090 |
Why?
| | DNA, Viral | 1 | 2011 | 349 | 0.080 |
Why?
| | Paromomycin | 1 | 2009 | 2 | 0.080 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.080 |
Why?
| | Entamoeba histolytica | 1 | 2009 | 7 | 0.080 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 12 | 0.080 |
Why?
| | Metronidazole | 1 | 2009 | 19 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2023 | 773 | 0.080 |
Why?
| | Drainage | 1 | 2009 | 145 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2023 | 9049 | 0.070 |
Why?
| | Animals | 6 | 2018 | 31565 | 0.070 |
Why?
| | Human Experimentation | 1 | 2007 | 12 | 0.070 |
Why?
| | Insect Bites and Stings | 1 | 2007 | 13 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 29 | 0.070 |
Why?
| | Plasmodium falciparum | 1 | 2007 | 27 | 0.070 |
Why?
| | Malaria, Falciparum | 1 | 2007 | 25 | 0.070 |
Why?
| | Viral Proteins | 1 | 2009 | 281 | 0.070 |
Why?
| | Disease Progression | 2 | 2023 | 2371 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4595 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3039 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 519 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2355 | 0.060 |
Why?
| | Safety | 1 | 2007 | 298 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1331 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 4 | 0.060 |
Why?
| | Genotype | 1 | 2009 | 1757 | 0.060 |
Why?
| | Pneumonia | 1 | 2009 | 563 | 0.050 |
Why?
| | Acetamides | 1 | 2023 | 25 | 0.050 |
Why?
| | Bradycardia | 1 | 2023 | 48 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 12 | 0.050 |
Why?
| | Vaccination Coverage | 1 | 2023 | 63 | 0.050 |
Why?
| | Multiple Organ Failure | 1 | 2023 | 116 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 42 | 0.050 |
Why?
| | Machine Learning | 1 | 2023 | 315 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2272 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 614 | 0.040 |
Why?
| | Databases, Factual | 1 | 2022 | 1125 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 385 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1080 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 16 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1447 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 607 | 0.030 |
Why?
| | Southwestern United States | 1 | 2015 | 90 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 2784 | 0.030 |
Why?
| | Cats | 1 | 2015 | 193 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 2384 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 331 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 2885 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4402 | 0.030 |
Why?
| | DNA, Helminth | 1 | 2013 | 16 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1469 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 990 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2505 | 0.020 |
Why?
| | Cross Reactions | 1 | 2009 | 118 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 137 | 0.020 |
Why?
| | Age Distribution | 1 | 2009 | 341 | 0.020 |
Why?
| | Parasitemia | 1 | 2007 | 9 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 787 | 0.020 |
Why?
|
|
Rao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|